

# MEDICAL ASSISTANCE BULLETIN

|                                                                            |                                               |                                                                                                                                                                                     |
|----------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ISSUE DATE</b><br><br>January 24, 2024                                  | <b>EFFECTIVE DATE</b><br><br>January 24, 2024 | <b>NUMBER</b><br><br>99-24-01                                                                                                                                                       |
| <b>SUBJECT</b><br><br>Medical Assistance Program Vaccine<br>Desk Reference |                                               | <b>BY</b><br><br><br>Sally A. Kozak,<br>Deputy Secretary<br>Office of Medical Assistance Programs |

**IMPORTANT REMINDER:** All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

## **PURPOSE:**

The purpose of this bulletin is to issue the Medical Assistance Program Vaccine Desk Reference.

## **SCOPE:**

This bulletin applies to all providers enrolled in the Medical Assistance (MA) Program that may administer vaccines to MA beneficiaries in the Fee-for-Service (FFS) delivery system or in the managed care delivery system. Providers rendering services to MA beneficiaries in the managed care delivery system should address any coding or rate-related questions to the appropriate MA managed care organization.

## **BACKGROUND/DISCUSSION:**

The Department of Human Services (Department) provides coverage to children and adult MA beneficiaries for certain vaccines, including but not limited to all vaccines recommended by the Advisory Committee on Immunization Practices. The Department has issued separate bulletins about MA coverage of individual vaccines and their administration. In order to provide an integrated resource for providers to use when billing for the administration of vaccines in the MA Program, the Department has developed an MA Program Vaccine Desk Reference.

### **COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:**

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at  
<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>.

The desk reference allows MA enrolled providers to view Current Procedural Terminology Codes (CPT) and Code Descriptions open on the MA Program Fee Schedule that are used for the administration of vaccines. The MA Program Vaccine Desk Reference will be updated when new procedure codes for the administration of vaccines are added to the MA Program Fee Schedule or there are updates to the current procedure codes. The desk reference will be available on the “Medical Assistance for Providers” webpage at: <https://www.dhs.pa.gov/providers/Providers/Pages/Medical-Assistance-for-Providers.aspx>.

**PROCEDURE:**

MA providers may bill the MA Program for the administration of vaccines using the CPT codes identified in the MA Program Vaccine Desk Reference. Billing instructions and additional Information about specific MA-covered vaccines can be found using the bulletin search which is available on the Department’s website at: <https://www.dhs.pa.gov/docs/For-Providers/Pages/Bulletin-Search.aspx>.

MA providers may also bill the MA Program for vaccines for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers can access the Pharmacy Services Covered Drugs Search Tool at the link below: <https://www.humanservices.state.pa.us/CoveredDrugs/CoveredDrugs/Index>.

Providers are reminded that they may not bill or receive payment from the MA Program for the cost of a vaccine or its administration when it is available through other sources.

**ATTACHMENT:**

Medical Assistance Program Vaccine Desk Reference, Effective January 24, 2024

**Medical Assistance Program Vaccine Desk Reference**  
**Effective January 24, 2024**

| Procedure Code | National Code Description                                                                                                                            |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| 90380          | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use                                                |
| 90381          | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use                                                  |
| 90581          | Anthrax vaccine, for subcutaneous or intramuscular use                                                                                               |
| 90585          | Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use                                                                  |
| 90587          | Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use                                                                            |
| 90589          | Chikungunya virus vaccine, live attenuated, for intramuscular use                                                                                    |
| 90611          | Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use |
| 90619          | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use                     |
| 90620          | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use                  |
| 90621          | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use                                  |
| 90622          | Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use                                                            |
| 90623          | Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use                          |
| 90625          | Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use                                                                                   |
| 90626          | Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use                                                            |
| 90627          | Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use                                                             |
| 90630          | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use                                                    |
| 90632          | Hepatitis A vaccine (HepA), adult dosage, for intramuscular use                                                                                      |
| 90633          | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use                                                       |
| 90636          | Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use                                                                 |
| 90647          | Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use                                               |
| 90648          | Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use                                                 |
| 90651          | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use                |
| 90656          | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use                                      |

**Medical Assistance Program Vaccine Desk Reference**  
**Effective January 24, 2024**

| Procedure Code | National Code Description                                                                                                                                                                                             |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 90662          | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use                                                                           |
| 90670          | Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use                                                                                                                                              |
| 90671          | Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use                                                                                                                                              |
| 90672          | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use                                                                                                                                               |
| 90674          | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use                                                           |
| 90675          | Rabies vaccine, for intramuscular use                                                                                                                                                                                 |
| 90677          | Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use                                                                                                                                              |
| 90678          | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use                                                                                                                                   |
| 90679          | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use                                                                                                                    |
| 90680          | Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use                                                                                                                                             |
| 90681          | Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use                                                                                                                                       |
| 90682          | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use                                                  |
| 90683          | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use                                                                                                                                  |
| 90685          | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL, for intramuscular use                                                                                                          |
| 90686          | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use                                                                                                    |
| 90687          | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use                                                                                                                      |
| 90688          | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use                                                                                                                       |
| 90691          | Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use                                                                                                                                            |
| 90696          | Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use                                 |
| 90697          | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use |
| 90698          | Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use                                                    |
| 90700          | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use                                                                     |
| 90702          | Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use                                                                                             |

**Medical Assistance Program Vaccine Desk Reference**  
**Effective January 24, 2024**

| Procedure Code | National Code Description                                                                                                                                                                   |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 90707          | Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use                                                                                                                  |
| 90710          | Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use                                                                                                           |
| 90713          | Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use                                                                                                                |
| 90714          | Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use                                                   |
| 90715          | Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use                                                |
| 90716          | Varicella virus vaccine (VAR), live, for subcutaneous use                                                                                                                                   |
| 90717          | Yellow fever vaccine, live, for subcutaneous use                                                                                                                                            |
| 90723          | Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use                                            |
| 90732          | Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use |
| 90734          | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use                          |
| 90736          | Zoster (shingles) vaccine (HZV), live, for subcutaneous injection                                                                                                                           |
| 90738          | Japanese encephalitis virus vaccine, inactivated, for intramuscular use                                                                                                                     |
| 90739          | schedule, for intramuscular use                                                                                                                                                             |
| 90743          | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use                                                                                                              |
| 90744          | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use                                                                                             |
| 90746          | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use                                                                                                            |
| 90747          | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use                                                                             |
| 90749          | Unlisted vaccine/toxoid                                                                                                                                                                     |
| 90750          | Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use                                                                                                    |
| 90756          | Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use                                                    |
| 90758          | Zaire ebolavirus vaccine, live, for intramuscular use                                                                                                                                       |
| 90759          | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use                                                                            |
| G0008          | Administration of influenza virus vaccine                                                                                                                                                   |
| G0009          | Administration of pneumococcal vaccine                                                                                                                                                      |

**Medical Assistance Program Vaccine Desk Reference**  
**Effective January 24, 2024**

| Procedure Code             | National Code Description                                                                                                                                                                                         |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>SARS-CoV-2 Vaccines</b> |                                                                                                                                                                                                                   |
| 91304                      | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use |
| 91318                      | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use              |
| 91319                      | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use             |
| 91320                      | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use             |
| 91321                      | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use                                                     |
| 91322                      | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use                                                      |